替加环素联合异帕米星治疗多重耐药鲍曼不动杆菌肺炎的临床疗效及安全性观察  

Effectiveness and safety observation of Tigecycline plus Isepamicin in MDR-AB patients with pneumonia

作　　者：张德良 Zhang Deliang(Department Of Respiratory Medicine,The Second Hospital Of Longyan,Xinluo District,Longyan City,Fujian Province,364000)

机构地区：[1]福建省龙岩市新罗区龙岩市第二医院呼吸内科,龙岩364000

出　　处：《北方药学》2020年第6期154-155,共2页Journal of North Pharmacy

摘　　要：目的:研究多重耐药鲍曼不动杆菌(MDR-AB)肺炎采用替加环素联合异帕米星治疗的临床效果。方法:选取2017年12月—2019年12月本院收治的86例MDR-AB肺炎患者作为研究对象,采用抽签法分为两组,各43例。参照组采用头孢哌酮舒巴坦静滴治疗,研究组采用替加环素联合异帕米星治疗,对两组临床疗效进行分析。结果:对比两组临床疗效,研究组高于参照组,差异显著(P<0.05);分析两组PCT、IL-6、TNF-α、CRP指标,治疗前两组无显著差异(P>0.05),治疗后,研究组均低于参照组,差异显著(P<0.05);两组不良反应发生率对比,研究组低于参照组,差异显著(P<0.05)。结论:对MDR-AB肺炎给予替加环素联合异帕米星治疗能显著缓解临床症状,控制炎症反应,且用药后不良反应发生率低,安全性高,可改善预后,加快恢复速度,促使治疗进展能够更加顺利。Objective:To study the clinical effect of Tigecycline plus Isepamicin in MDR-AB(multi-drug resistant acinetobacter baumannii)patients with pneumonia.Methods:86 MDR-AB patients with pneumonia treated from December 2017 to December 2019 in our hospital were screened out and grouped by lottery method,43 cases in each group.Reference group took intravenous injection of sulbactam and cefoperazone;research group took Tigecycline and Isepamicin.Therapeutic effects were analyzed.Results:The overall effective rate in the research group was significantly higher than reference group(P<0.05);PCT(procalcitonin),IL-6(interleukin-6),TNF-α(tumor necrosis factor-α)and CRP(C-reactive protein)levels between groups were not significantly different(P>0.05);after treatment,related indicators in the research group were significantly lower than reference group(P<0.05);the adverse event rate in the research group was significantly lower than reference group(P<0.05).Conclusion:Tigecycline and Isepamicin can remarkably relieve the clinical symptoms,control the inflammatory response,reduce the adverse event rate,improve the treatment safety and prognosis,promote the fast recovery and accelerate the treatment progress.

关 键 词：多重耐药鲍曼不动杆菌 替加环素 异帕米星 头孢哌酮舒巴坦 肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]